Natasha Giordano
2021
In 2021, Natasha Giordano earned a total compensation of $3.2M as President, Chief Executive Officer and Director at Dipexium Pharmaceuticals, a 32% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $306,075 |
|---|---|
| Option Awards | $2,332,000 |
| Salary | $556,500 |
| Other | $22,303 |
| Total | $3,216,878 |
Giordano received $2.3M in option awards, accounting for 72% of the total pay in 2021.
Giordano also received $306.1K in non-equity incentive plan, $556.5K in salary and $22.3K in other compensation.
Rankings
In 2021, Natasha Giordano's compensation ranked 4,158th out of 12,405 executives tracked by ExecPay. In other words, Giordano earned more than 66.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,158 out of 12,405 | 67th |
Division Manufacturing | 1,712 out of 5,494 | 69th |
Major group Chemicals And Allied Products | 708 out of 2,369 | 70th |
Industry group Drugs | 630 out of 2,090 | 70th |
Industry Pharmaceutical Preparations | 444 out of 1,537 | 71st |
Source: SEC filing on September 29, 2022.
Giordano's colleagues
We found two more compensation records of executives who worked with Natasha Giordano at Dipexium Pharmaceuticals in 2021.